








































CHE）などのドーパ類縁化合物により抑制される6  ， 7）．
さらに，大動脈神経刺激およびフェニレフリン静注によ
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　Identification of novel bioactive substances is an important issue in medical and biological research. Generally, 
L-3,4-dihydroxyphenylalanine (L-DOPA, DOPA, levodopa) is considered to be an inert amino acid. The 
pharmacological actions of DOPA have been believed to be caused through its conversion to dopamine by aromatic 
L-amino acid decarboxylase. On the other hand, accumulating evidence suggests that DOPA is a neurotransmitter. 
Recently, G-protein coupled receptor GPR143, the gene product of ocular albinism-1, was identified as a receptor 
for DOPA. Although the functional analysis of GPR143 shows novel actions of DOPA, the physiological roles of 
DOPA are not fully understood. This review summarizes the background of the DOPA neurotransmitter hypothesis 
and the current understanding of the physiological roles of DOPA.
